197 related articles for article (PubMed ID: 33757387)
21. Highly predictive CoMFA and CoMSIA models for two series of stromelysin-1 (MMP-3) inhibitors elucidate S1' and S1-S2' binding modes.
Amin EA; Welsh WJ
J Chem Inf Model; 2006; 46(4):1775-83. PubMed ID: 16859309
[TBL] [Abstract][Full Text] [Related]
22. Structure-Guided Design, Synthesis, and Characterization of Next-Generation Meprin β Inhibitors.
Ramsbeck D; Hamann A; Richter G; Schlenzig D; Geissler S; Nykiel V; Cynis H; Schilling S; Buchholz M
J Med Chem; 2018 May; 61(10):4578-4592. PubMed ID: 29694039
[TBL] [Abstract][Full Text] [Related]
23. Virtual High-Throughput Screening for Matrix Metalloproteinase Inhibitors.
Choi JY; Fuerst R
Methods Mol Biol; 2017; 1579():259-271. PubMed ID: 28299742
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
26. Bacterial extracellular zinc-containing metalloproteases.
Häse CC; Finkelstein RA
Microbiol Rev; 1993 Dec; 57(4):823-37. PubMed ID: 8302217
[TBL] [Abstract][Full Text] [Related]
27. Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Tauro M; Loiodice F; Ceruso M; Supuran CT; Tortorella P
Bioorg Med Chem Lett; 2014 Jun; 24(12):2617-20. PubMed ID: 24813742
[TBL] [Abstract][Full Text] [Related]
28. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Laghezza A; Tortorella P; Agamennone M
ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of ferulic Acid amides as selective matrix metalloproteinase inhibitors.
Shi ZH; Li NG; Shi QP; Tang H; Tang YP; Li W; Yin L; Yang JP; Duan JA
Med Chem; 2013 Nov; 9(7):947-54. PubMed ID: 23061601
[TBL] [Abstract][Full Text] [Related]
30. Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.
Lenci E; Innocenti R; Di Francescantonio T; Menchi G; Bianchini F; Contini A; Trabocchi A
Bioorg Med Chem; 2019 May; 27(9):1891-1902. PubMed ID: 30926311
[TBL] [Abstract][Full Text] [Related]
31. Catechol-rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR).
Zinglé C; Tritsch D; Grosdemange-Billiard C; Rohmer M
Bioorg Med Chem; 2014 Jul; 22(14):3713-9. PubMed ID: 24890653
[TBL] [Abstract][Full Text] [Related]
32. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study.
Marcial BL; Sousa SF; Barbosa IL; Dos Santos HF; Ramos MJ
J Phys Chem B; 2012 Nov; 116(46):13644-54. PubMed ID: 23121406
[TBL] [Abstract][Full Text] [Related]
33. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
34. Bioactive conformation of stromelysin inhibitors determined by transferred nuclear Overhauser effects.
Gonnella NC; Bohacek R; Zhang X; Kolossváry I; Paris CG; Melton R; Winter C; Hu SI; Ganu V
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):462-6. PubMed ID: 7831311
[TBL] [Abstract][Full Text] [Related]
35. Identification of Non-Zinc Binding Inhibitors of MMP-2 Through Virtual Screening and Subsequent Rescoring.
Shamsara J
Drug Res (Stuttg); 2018 Sep; 68(9):529-535. PubMed ID: 29614516
[TBL] [Abstract][Full Text] [Related]
36. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
37. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells.
Nakaya H; Osawa G; Iwasaki N; Cochran DL; Kamoi K; Oates TW
J Periodontol; 2000 Jul; 71(7):1158-66. PubMed ID: 10960024
[TBL] [Abstract][Full Text] [Related]
38. First insight into structure-activity relationships of selective meprin β inhibitors.
Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
[TBL] [Abstract][Full Text] [Related]
39. Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives.
Di Leo R; Cuffaro D; Rossello A; Nuti E
Molecules; 2023 May; 28(11):. PubMed ID: 37298854
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 7-aminophenanthridin-6-one as a new scaffold for matrix metalloproteinase inhibitors with multitarget neuroprotective activity.
Rocchi D; Blázquez-Barbadillo C; Agamennone M; Laghezza A; Tortorella P; Vicente-Zurdo D; Rosales-Conrado N; Moyano P; Pino JD; González JF; Menéndez JC
Eur J Med Chem; 2021 Jan; 210():113061. PubMed ID: 33310289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
